Keywords: NSCLC, EGFR mutations, targeted therapy, chemotherapy, meta-analysis
non-small-cell lung cancer, Immune checkpoint inhibitors, chemotherapy, efficacy, dexamethasone
PD-1, PD-L1, pulmonary lymphoepithelioma-like carcinoma, Immunotherapy, Chemotherapy, Perioperative, surgery
Immunotherapy, non-small cell lung cancer, serum amyloid A, biomarker, early kinetics